|
| |
BioPortfolio's Approved Drugs DatabaseVancocinVancomycin HydrochlorideDownload PDF containing detailed information.
Press Releases About Vancocin:
|
 |
| Optimer Pharmaceuticals Completes Enrollment in Second Fidaxomicin Phase 3 Clinical Trial in Patients With Clostridium difficile Infection |
12th November, 2009 |
Optimer Pharmaceuticals, Inc. |
SAN DIEGO, Nov. 12 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that it has completed enrollment in the second of two pivotal Phase 3 clinical trials
|
| ViroPharma Incorporated Reports Third Quarter 2009 Financial Results |
28th October, 2009 |
ViroPharma Incorporated |
-- Delivered positive cash flows from operations of $42 million for the
nine months ended September 30, 2009.
Net sales were $80.6 million and $222.6 million for the three and nine
|
| ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors |
8th June, 2009 |
ViroPharma Incorporated |
EXTON, Pa., June 8 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the appointment of Frank Baldino, Jr., Ph.D. to its board of directors.
Dr. Baldino brings several
|
| ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema |
4th June, 2009 |
ViroPharma Incorporated |
- Company Also Granted Expansion of Prophylaxis Therapy Label to Include Patient Labeling for Self-Administration -
EXTON, Pa., June 4 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM
|
| Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI |
2nd June, 2009 |
Optimer Pharmaceuticals, Inc. |
SAN DIEGO, June 2 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that additional results from its North American Phase 3 clinical study of fidaxomicin in patients
|
Companies working in the area of Vancocin from Bioportfolio's Biocorporate database : | |
| Company Name | |
At ViroPharma, we are dedicated to transforming the lives of patients through the commercialization of new and important medicines. Our goal is to focus on developing and marketing innovative products...
www.viropharma.com/ View full profile
| |
This page has been viewed 32 times
Browse BioPortfolio's InDepth service - alphabetically:
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
or by Most Publications, recently searched for, or
most viewed.
Search for Vancocin across BioPortfolio, or for Vancocin Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH.
Thumbshots from Thumbshots.org
|
